Ali Motahharynia

Dr. Ali Motahharynia

Isfahan University of Medical Sciences, Isfahan, Iran
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMahsa Sheikholeslami
Mahsa Sheikholeslami
NMNavid Mazrouei
Navid Mazrouei
YGYousof Gheisari
Yousof Gheisari
AFAfshin Fasihi
Afshin Fasihi
MIMatin Irajpour
Matin Irajpour
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
Traditional drug design faces significant challenges due to inherent chemical and biological complexities, often resulting in high failure rates in clinical trials. Deep learning advancements, particularly generative models, offer potential solutions to these challenges. One promising algorithm is DrugGPT, a transformer-based model, that generates small molecules for input protein sequences. Although promising, it generates both chemically valid and invalid structures and does not incorporate the features of approved drugs, resulting in time-consuming and inefficient drug discovery. To address these issues, we introduce DrugGen, an enhanced model based on the DrugGPT structure. DrugGen is fine-tuned on approved drug-target interactions and optimized with proximal policy optimization. By giving reward feedback from protein–ligand binding affinity prediction using pre-trained transformers (PLAPT) and a customized invalid structure assessor, DrugGen significantly improves performance. Evaluation across multiple targets demonstrated that DrugGen achieves 100% valid structure generation compared to 95.5% with DrugGPT and produced molecules with higher predicted binding affinities (7.22 [6.30–8.07]) compared to DrugGPT (5.81 [4.97–6.63]) while maintaining diversity and novelty. Docking simulations further validate its ability to generate molecules targeting binding sites effectively. For example, in the case of fatty acid-binding protein 5 (FABP5), DrugGen generated molecules with superior docking scores (FABP5/11, -9.537 and FABP5/5, -8.399) compared to the reference molecule (Palmitic acid, -6.177). Beyond lead compound generation, DrugGen also shows potential for drug repositioning and creating novel pharmacophores for existing targets. By producing high-quality small molecules, DrugGen provides a high-performance medium for advancing pharmaceutical research and drug discovery.

18 February 2022 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
SMShiva Moein
Shiva Moein
FKFarnoush Kiyanpour
Farnoush Kiyanpour
KMKobra Moradzadeh
Kobra Moradzadeh
MYMoein Yaqubi
Moein Yaqubi
YGYousof Gheisari
Yousof Gheisari
Olfactory receptors (ORs) which are mainly known as odor-sensors in the olfactory epithelium are shown to be expressed in several non-sensory tissues. Despite the specified role of some of these receptors in normal physiology of the kidney, little is known about their potential effect in renal disorders. In this study, using the holistic view of systems biology, it was determined that ORs are significantly changed during the progression of kidney fibrosis. For further validation, common differentially expressed ORs resulted from reanalysis of two time-course microarray datasets were selected for experimental evaluation in a validated murine model of unilateral ureteral obstruction (UUO). Transcriptional analysis by real-time quantitative polymerase chain reaction demonstrated considerable changes in the expression pattern of Olfr433, Olfr129, Olfr1393, Olfr161, and Olfr622 during the progression of kidney fibrosis. For localization of these ORs, single-cell RNA-sequencing datasets of normal and UUO mice were reanalyzed. Results showed that Olfr433 is highly expressed in macrophages in day-2 and 7 post-injury in UUO mice and not in normal subgroups. Besides, like previous findings, Olfr1393 was shown to be expressed prominently in the proximal tubular cells of the kidney. In conclusion, our combinatorial temporal approach to the underlying mechanisms of chronic kidney disease highlighted the potential role of ORs in progression of fibrosis. The expression of Olfr433 in the macrophages provides some clue about its relation to molecular mechanisms promoted in the fibrotic kidney. The proposed ORs in this study could be the subject of further functional assessments in the future.

24 June 2025 in Bioinformatics
Verified
Journal Article
Open access
NBNiloofar Borhani
Niloofar Borhani
IIIman Izadi
Iman Izadi
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
MSMahsa Sheikholeslami
Mahsa Sheikholeslami
YGYousof Gheisari
Yousof Gheisari
Motivation: Target discovery is crucial in drug development, especially for complex chronic diseases. Recent advances in high-throughput technologies and the explosion of biomedical data have highlighted the potential of computational druggability prediction methods. However, most current methods rely on sequence-based features with machine learning, which often face challenges related to hand-crafted features, reproducibility, and accessibility. Moreover, the potential of raw sequence and protein structure has not been fully investigated. Results: Here, we leveraged both protein sequence and structure using deep learning techniques, revealing that protein sequence, especially pre-trained embeddings, is more informative than protein structure. Next, we developed DrugTar, a high-performance deep learning algorithm integrating sequence embeddings from the ESM-2 pre-trained protein language model with gene ontologies to predict druggability. DrugTar achieved areas under the curve and precision–recall curve values of 0.94, outperforming state-of-the-art methods. In conclusion, DrugTar streamlines target discovery as a bottleneck in developing novel therapeutics. Availability and implementation: DrugTar is available as a web server at www.DrugTar.com. The data and source code are at https://github.com/NBorhani/DrugTar.

5 July 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
SNSaba Naghavi
Saba Naghavi
VSVahid Shaygannejad
Vahid Shaygannejad
IAIman Adibi
Iman Adibi

13 November 2022 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
APAhmad Pourmohammadi
Ahmad Pourmohammadi
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
VSVahid Shaygannejad
Vahid Shaygannejad
FAFereshteh Ashtari
Fereshteh Ashtari
IAIman Adibi
Iman Adibi
MSMehdi Sanayei
Mehdi Sanayei

16 June 2022 in eNeurologicalSci
Verified
Journal Article
Open access
Ali MotahharyniaAli Motahharynia
Ali Motahharynia
SNSaba Naghavi
Saba Naghavi
VSVahid Shaygannejad
Vahid Shaygannejad
IAIman Adibi
Iman Adibi
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could prompt various neurological complications. Abrupt visual disturbance was reported as a rare severe manifestation of post-coronavirus disease 2019 (COVID-19). Autoimmune conditions were assumed to have an undeniable role in creation of such circumstances. This report presents a 69-year-old woman with sudden bilateral blindness three weeks after recovering from a SARS-CoV-2 infection. Demyelination due to COVID-19-related autoimmune disorder of the central nervous system (CRAD-C) was considered to be the etiology of her bilateral blindness. Due to her progressive demyelination, immunosuppressive treatments were administered, which resulted in stabilizing post-COVID-19 demyelinating lesions. Accordingly, in the case of COVID-19-related neurological deficits, especially the acute and progressive symptoms, there should be great consideration of autoimmune response to prevent serious complications; hence early diagnosis, treatment, and long-term assessment of patients are necessitated.